Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.

Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: a systematic review and economic evaluation.

Bryant J, Brodin H, Loveman E, Clegg A.

Int J Technol Assess Health Care. 2007 Winter;23(1):63-70. Review.

PMID:
17234018
2.

The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review.

Bryant J, Brodin H, Loveman E, Payne E, Clegg A.

Health Technol Assess. 2005 Sep;9(36):1-150, iii. Review.

3.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

4.

Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.

Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA.

Ann Intern Med. 1997 Jan 1;126(1):1-12.

PMID:
8992917
5.

Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence.

Lynd LD, O'Brien BJ.

J Cardiovasc Electrophysiol. 2003 Sep;14(9 Suppl):S99-103. Review.

PMID:
12950529
6.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

7.

Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials.

Ezekowitz JA, Armstrong PW, McAlister FA.

Ann Intern Med. 2003 Mar 18;138(6):445-52. Review.

PMID:
12639076
8.

Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.

Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA.

Am Heart J. 2002 Sep;144(3):440-8.

PMID:
12228780
9.

Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.

Colquitt JL, Mendes D, Clegg AJ, Harris P, Cooper K, Picot J, Bryant J.

Health Technol Assess. 2014 Aug;18(56):1-560. doi: 10.3310/hta18560. Review.

10.

Cost-effectiveness of implantable cardioverter-defibrillators.

Sanders GD, Hlatky MA, Owens DK.

N Engl J Med. 2005 Oct 6;353(14):1471-80.

11.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

12.

Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.

Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S.

J Am Coll Cardiol. 2006 Jul 4;48(1):112-21. Epub 2006 Jun 9.

13.

Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias.

Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W.

Ann Noninvasive Electrocardiol. 2005 Oct;10(4 Suppl):67-83.

PMID:
16274418
14.

Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.

Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK.

Ann Intern Med. 2001 Nov 20;135(10):870-83.

PMID:
11712877
15.

Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.

Parkes J, Bryant J, Milne R.

Health Technol Assess. 2000;4(26):1-69. Review.

16.
17.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

18.

Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.

Filion KB, Xie X, van der Avoort CJ, Dendukuri N, Brophy JM.

Int J Technol Assess Health Care. 2009 Apr;25(2):151-60. doi: 10.1017/S0266462309090205. Epub 2009 Mar 31.

PMID:
19331707
19.

The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.

Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG.

Eur Heart J. 2007 Jan;28(1):42-51. Epub 2006 Nov 16.

20.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

Items per page

Supplemental Content

Write to the Help Desk